Market Place
Sourcing Support
UK court orders GSK to pay AstraZeneca royalties on total sales of Zejula
06 Apr 2023 //
REUTERS
Merck`s Vaxneuvance lead departs for Affinivax—Chutes & Ladders
13 Aug 2021 //
FIERCEBIOTECH
With Tesaro staff and expertise in the mix
14 Jan 2020 //
FIERCE PHARMA
GSK, AZ-Merck PARP data heap pressure on Clovis: analysts
02 Oct 2019 //
FIERCE PHARMA
AstraZeneca rounds out ESMO for expanded biomarker in prostate cancer
30 Sep 2019 //
ENDPTS
AbbVie`s PARP inhibitor veliparib finally gets a win, but can it compete?
29 Sep 2019 //
FIERCE BIOTECH
Barron exhorts GSK scientists to take `smart risks`
22 Jul 2019 //
FIERCE BIOTECH
GSK`s Zejula racks up first-line maintenance win in ovarian cancer
16 Jul 2019 //
FIERCE PHARMA
Evotec spins off cancer tech into new Breakpoint company
08 Jul 2019 //
PM LIVE
Carrick hires ex-Tesaro CFO, shifts focus toward U.S.
28 Jun 2019 //
FIERCE BIOTECH
Who`s the next Big Pharma takeout target? Biogen, uniQure, AZ top the list
26 Jun 2019 //
FIERCE PHARMA
GSK wins speedy FDA Zejula review in ovarian cancer niche
25 Jun 2019 //
FIERCE PHARMA
GlaxoSmithKline R&D reorganization triggers layoffs at Stevenage
17 Apr 2019 //
ENDPTS
GSK`s Tesaro taps Scott Foley on ovarian cancer maintenance push
07 Mar 2019 //
FIERCE PHARMA
Hal Barron’s GSK team continues to cull resp drugs in big shift to oncology R&D
06 Feb 2019 //
ENDPTS
GSK looks to oncology for growth as Advair generic hits
06 Feb 2019 //
FIERCE PHARMA
China`s NMPA Grants Priority Review To Zai`s PARP Inhibitor
29 Jan 2019 //
Zai Lab nabs speedy China regulatory review for PARP drug Zejula
28 Jan 2019 //
ENDPTS
No bidding war for Loxo, so did Lilly overpay?
19 Jan 2019 //
FIERCE PHARMA
GSK extends expiration date for Tesaro offer
16 Jan 2019 //
PHARMA TIMES
JPM recap: Must-reads of the week, from FDA to IPO to M&A
12 Jan 2019 //
FIERCE PHARMA
Buckle up, it’s going to be a bumpy ride
11 Jan 2019 //
ENDPTS
Clovis CEO to potential bidders: Step right up
11 Jan 2019 //
FIERCE PHARMA
A biotech`s M&A invitation, Editas` next CRISPR step and more from day 3
11 Jan 2019 //
BIOPHARMA DIVE
First-line ovarian approval cements AZ’s Lynparza lead
20 Dec 2018 //
PM LIVE
Clovis should put itself up for sale, activist Armistice says: report
19 Dec 2018 //
FIERCE PHARMA
Tesaro execs split $304M windfall from $5.1B GlaxoSmithKline buyout
17 Dec 2018 //
ENDPTS
Anatomy of a long-delayed biotech buyout: Tesaro wound up in GSK’s eager arms
15 Dec 2018 //
ENDPTS
With its stock price beaten down, abandoned by potential bidders
13 Dec 2018 //
ENDPTS
Will Clovis be the next PARP maker to get swallowed up?
08 Dec 2018 //
FIERCE PHARMA
GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca
04 Dec 2018 //
XCONOMY
Tesaro Is Now An Attractive Acquisition Target
21 Nov 2018 //
SEEKING ALPHA
Tesaro stock soars on another report the PARP player is exploring a sale
19 Nov 2018 //
ENDPTS
AstraZeneca`s Lynparza shown to put brakes on ovarian cancer
23 Oct 2018 //
REUTERS
Myriad signs BRCA IVD commercialization deal with Pfizer
10 Oct 2018 //
FIERCE BIOTECH
Newly discovered ALS mechanism could point the way to novel drugs
06 Sep 2018 //
FIERCE BIOTECH
PARP inhibitors for ALS? Penn researchers post promising finds in brain disease
10 Aug 2018 //
ENDPTS
Cha-ching: Small biotechs write some of America`s biggest paychecks
07 Aug 2018 //
FIERCE PHARMA
Epizyme poaches SQZ Biotech, Tesaro vet Agarwal as CMO
23 Jul 2018 //
FIERCE BIOTECH
Could even more cancer patients benefit from PARP inhibitors?
16 Jul 2018 //
FIERCE BIOTECH
Tesaro stock rockets as rumours of Roche takeover abound
22 Jun 2018 //
PHARMAPHORUM
Tesaro`s Varubi (Rolapitant) Approved in US For Nausea and Vomiting
03 Sep 2015 //
FDA
Tesaro licenses PDUFA-status candidate rolapitant to China`s Jiangsu Hengrui
03 Aug 2015 //
FIERCE PHARMA ASIA
